Final Thoughts on S1P Receptor Modulators in Multiple Sclerosis
Bruce Cree, MD, PhD, MAS, presents his final thoughts for clinicians on the safety, efficacy, and tolerability of sphinogine-1-phospate (S1P) receptor modulators in the treatment of multiple sclerosis (MS).
EP: 1.S1P Receptor Modulators and the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis
EP: 2.Tissue Selectivity of S1P Receptor Modulator
EP: 3.Safety Profile of S1P Receptor Modulators for Multiple Sclerosis
EP: 4.Monitoring Patients With Relapsing-Remitting Multiple Sclerosis on S1P Receptor Modulator
EP: 5.Switching Patients With Multiple Sclerosis to S1P Receptor Modulator
EP: 6.The Safety Data of Ozanimod in Multiple Sclerosis
EP: 7.The Safety of Other S1P Receptor Modulators in Multiple Sclerosis
EP: 8.Clinical Pearls for Treating Relapsing-Remitting Multiple Sclerosis With S1P Receptor Modulators
EP: 9.S1P Receptor Modulators in Multiple Sclerosis
EP: 10.Selecting S1P Receptor Modulators in Multiple Sclerosis
EP: 11.Long-term Data With Ozanimod in Relapsing-Remitting Multiple Sclerosis
EP: 12.Long-Term Data With Other S1P Receptor Modulators in Multiple Sclerosis
EP: 13.Long-term Immunological Impact of Drug-Modifying Therapies in Multiple Sclerosis
EP: 14.Expert Advice on Multiple Sclerosis Treatment Cessation and Disease Rebound
EP: 15.Emerging Disease-Modifying Therapy Data in Multiple Sclerosis
EP: 16.Final Thoughts on S1P Receptor Modulators in Multiple Sclerosis
Transcript
Bruce Cree, MD, PhD, MAS: S1P [sphinogine-1-phospate] receptor modulators, as a class, do offer a safe, well-tolerated, and highly efficacious therapeutic option that is an oral therapy for our patients, and is, generally speaking, fairly easily reversible in the sense that the medications can be discontinued. They, especially the next generation ones, have a relatively short half-life. So, the therapeutic effects of these medications can resolve fairly quickly after discontinuation. For patients who are not looking at the long-term commitment that anti-CD20 monoclonal antibodies have, these medications, as a class, do offer patients a combination of high degrees of efficacy, excellent safety profiles, and really fantastic tolerability for treatment of relapsing forms of MS, including active secondary progressive MS.
Transcript edited for clarity.
